| 基于循环血微小RNA预测心脏再同步化治疗疗效 |
| |
| 引用本文： | 王菲,Saumya Das. 基于循环血微小RNA预测心脏再同步化治疗疗效[J]. 上海大学学报(自然科学版), 2016, 22(3): 265-269. DOI: 10.3969/j.issn.1007-2861.2016.04.019 |
| |
| 作者姓名： | 王菲 Saumya Das |
| |
| 作者单位： | 哈佛医学院附属麻省总院心脏内科, 波士顿02215, MA, 美国 |
| |
| 摘 要： | 心力衰竭是一类严重危害人类健康的重大疾病, 心脏再同步化是一种治疗心室收缩不同步的心力衰竭患者的疗法, 但并不是所有的患者都可以获益. 因此, 发掘可以预测心脏再同步化治疗反应性的生物标记物具有重大意义. 微小RNA 可以稳定地存在于循环血中, 反映各种疾病状态, 而本研究组的研究发现通过循环血微小RNA-30d 的高表达可以预测心脏再同步化治疗的反应性, 具有一定的应用前景.
|
| 关 键 词： | 微小RNA 生物标记物 心脏再同步化治疗 |
| 收稿时间： | 2016-06-13 |
Circulating miRNAs predict response to cardiac resynchronization therapy |
| |
| WANG Fei,Saumya Das. Circulating miRNAs predict response to cardiac resynchronization therapy[J]. Journal of Shanghai University(Natural Science), 2016, 22(3): 265-269. DOI: 10.3969/j.issn.1007-2861.2016.04.019 |
| |
| Authors: | WANG Fei Saumya Das |
| |
| Affiliation: | Cardiovascular Division, Massachusetts General Hospital of Harvard Medical School |
| |
| Abstract: | Heart failure (HF) is one of the most common syndrome seriously harmful to human health. Cardiac resynchronization therapy (CRT) is an exciting recent advancement for HF patient by targeting ventricular systolic dyssynchrony, but it has been proved that CRT cannot achieve hemodynamic or clinical benefit for all patients. It is very essential to find out biomarkers for predicting responsive patients. Circulating extracellular microRNAs(miRNAs) have emerged as novel biomarkers for many diseases. Recent study indicated that a high level of circulating miR-30d could predict response to CRT, which may have bright prospects in future research and application. |
| |
| Keywords: | biomarker microRNAs cardiac resynchronization therapy |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《上海大学学报(自然科学版)》浏览原始摘要信息 |
|
点击此处可从《上海大学学报(自然科学版)》下载免费的PDF全文 |
